We develop innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.
Learn More

ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future.

Clinical Trials

The company’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide that is being studied in multiple diseases.

Science

Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.

Month: October 2019

  • ONL Therapeutics Announces First Patient Treated in Phase I Study With ONL1204

    ONL Therapeutics Announces First Patient Treated in Phase I Study With ONL1204 ONL Therapeutics transformed into a clinical stage biopharmaceutical company with first-in-human study ANN ARBOR, MI – October 23, 2019 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first patient…

  • ONL Therapeutics Announces First-in-human Clinical Study With ONL1204

    ONL Therapeutics Announces First-in-human Clinical Study With ONL1204 Lead candidate ONL1204 advances into Phase I clinical study in retinal detachment in Australia ANN ARBOR, MI – October 8, 2019 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the initiation of the company’s First-in-Human…